The Sanyou Super Trillion Peptide Molecule Discovery Platform Was Officially Launched Today
Saturday, January 20, 2024
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. has officially introduced its state-of-the-art "Sanyou Super Trillion Peptide Molecule Discovery Platform."
This platform is a crucial element of the broader "Sanyou Super Trillion Innovative Biopharmaceutical Discovery Platform (STAL)," featuring an extensive library capacity of up to 3.05×10^12 CFU (30 trillion). Tailored for research and development in peptide-based drugs targeting conditions such as metabolic disorders, tumors, and applications in medical imaging and molecular diagnostics, the platform enables the creation of various novel drugs, including PDCs, RDCs, antibody fusion proteins, and cyclic peptides.
The Super Trillion Peptide Molecule Discovery Platform from Sanyou Biopharmaceuticals has been meticulously crafted through the examination of tens of thousands of natural amino acid sequences. Incorporating patented fusion tag proteins, assisted by AI design, and utilizing phage display technology with high-throughput screening, the platform ensures that the library sequences adhere to natural patterns, demonstrate high diversity, and undergo thorough target validation.
This advanced platform empowers Sanyou Pharmaceuticals to screen dozens to nearly a hundred lead molecules with substantial sequence variations for a single target. The screened peptides exhibit remarkably high affinity, and with the assistance of AI and structure-guided optimization, they can achieve levels in the nanomolar (nM) and sub-nanomolar (sub-nM) range.
Dr. Guojun Lang, CEO of Sanyou Biopharmaceuticals, remarked, "Peptide drugs offer high specificity, low immunogenicity, minimal toxicity, and applicability to various targets, including intracellular, extracellular, and membrane surfaces. The peptide drug market shows tremendous growth potential, with global sales reaching nearly $20 billion in 2023 for just one drug, Semaglutide. Establishing a peptide library is a pivotal step in peptide drug development and represents a technological challenge. Leveraging our extensive experience in innovative biopharmaceuticals and the construction of the STAL Super Trillion Antibody Library platform, Sanyou Biopharmaceuticals has successfully surmounted various technical challenges to complete the construction of the Super Trillion Peptide Molecule Discovery Platform. We believe that the launch of this platform will overcome the development challenges associated with peptide drugs and significantly accelerate the overall development process."
Source: prnewswire.com
